Joseph Pantginis

Applied Genetic Technologies Corp (NASDAQ: AGTC), a biotech focused on adeno-associated virus-based gene therapies for the treatment of rare diseases, reported disappointing results from an X-linked retinoschisis clinical study. The company also confirmed Biogen Inc (NASDAQ: BIIB) terminated...

Viking Therapeutics Inc (NASDAQ: VKTX), which focuses on therapies for metabolic and endocrine disorders, recently presented Phase 2 data for its non-alcoholic fatty liver disease, or NAFLD, treatment candidate VK2809 at the annual meeting of the American Association for the Study of Liver...

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) announced Tuesday the approval of its Tavalisse for chronic immune thrombocytopenia — an achievement prompting a 14-percent pop in its stock price. Analysts echoed investor enthusiasm, with H.C. Wainwright increasing its price target from $6.70 to $8...

Palatin Technologies, Inc. (NYSE: PTN), a biopharmaceutical company that focuses on treatments for diseases with significant unmet medical needs, boasts a lead asset, bremelanotide, that has an "arousing number of major boxes checked," according to H.C. Wainwright. The Analyst H.C....

Sellas Life Sciences Group Inc (NASDAQ: SLS) popped as much as 189 percent Monday after reporting “clinically meaningful activity” in interim data for its Phase 2b NeuVax trial. H.C. Wainwright liked the stock before it peaked, though, and it considers NeuVax just a footnote in the...

Analysts at H.C. Wainwright initiated coverage Thursday on two pharmaceutical companies developing cancer-related vaccines and treatments. Interpace: Efficient Diagnosis, Expanding Reimbursement Coverage Analyst Raghuram Selvaraju initiated coverage on Interpace Diagnostics Group, Inc. (NASDAQ:...

Strata Skin Sciences, Inc. (NASDAQ: SSKN), a nano-cap medical technology company that develops, commercializes and markets innovative products for the treatment of dermatologic conditions, has a more than 400 percent upside, according to HC Wainwright & Co's Joseph Pantginis. Pantginis...

Aptose Biosciences Inc (NASDAQ: APTO) is seeing a strong run in pre-market trading Thursday following H.C. Wainwright & Co's upgrade. The firm premised its opinion change on its belief that an inflection point may be drawing near. As such, the firm upgraded shares of Aptose from Neutral to...

Analysts at H.C. Wainwright & Co. continue to see Ligand Pharmaceuticals Inc. (NASDAQ: LGND) as a "core long term holding" for investors. The firm's Joseph Pantginis initiated coverage of the biopharmaceutical company with a Buy rating and $150 price target, mostly due to the company's business...

Data presented by Cytokinetics, Inc. (NASDAQ: CYTK) showed CK-107 has the ability to positively impact two different animal models of spinal muscular atrophy. Rodman & Renshaw’s Joseph Pantginis reiterated a Buy rating on the company, with a price target of $25. Positive Indications The...